microRNAは, 癌の発症・進展・薬剤耐性とも大きく関わることが明らかになっている。我々は, 子宮体癌においてエピジェネティックに発現抑制される癌抑制型microRNAとしてmiR-34bを同定し, さらにmiR-34bと抗癌剤の併用による抗腫瘍効果を検討した。
3種の子宮体癌細胞株に対しパクリタキセルを作用させた時は, 全ての細胞株においてmiR-34b添加時に細胞生存率の低下が認められた。また, HEC-1Bをヌードマウスの皮下に移植後, 28日目にはパクリタキセル+miR-34b群は他の群に比し有意に腫瘍径の縮小が認められた(P<0.05)。
microRNAs have key roles in the onset, development and drug resistance of cancer. We identified miR-34b as a tumor suppressor-type microRNA with expression that is epigenetically suppressed in endometrial cancer. In this study, the antitumor effect of combined miR-34b and antitumor drugs on endometrial cancer was examined. [Results] There was no change in cell viability after administration of miR-34b following application of cisplatin or adriamycin to HEC-108, HEC-1B and KLE cells. However, after treatment with paclitaxel, cell viability after administration of miR-34b decreased in all three cell lines. Tumor development occurred 14 days after transplantation of HEC-1B cells in nude mice. Drugs were administered on that day and thereafter. The tumor diameter significantly decreased in mice treated with paclitaxel + miR-34b compared with the results for other treatments (P<0.05). The GFP fluorescence signal also markedly decreased after treatment with paclitaxel + miR-34b.
|